The FASEB Journal · 2006 · 102 citations · 33 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyMolecular PharmacologyAngiogenesisAngiogenesis In CancerEnzyme InhibitionGrowth Factor SignalingLipid Biosynthesis InhibitionEndothelial ProliferationFatty Acid Synthase InhibitionFatty Acid Synthase InhibitorsFatty AcidsThioesterase DomainsVascular Endothelial Growth FactorVascular Endothelial Growth Factor InhibitionVascular Endothelial Growth Factor Receptors
Orlistat, an antiobesity drug, is cytostatic and cytotoxic to tumor cells (1). The antitumor activity of orlistat can be attributed to its ability to inhibit the thioesterase domain of fatty acid synthase (FAS). The objective of the present study was to test the effect of orlistat on endothelial cell proliferation and angiogenesis. Orlistat inhibits endothelial cell FAS, blocks the synthesis of fatty acids, and prevents endothelial cell proliferation. More significantly, orlistat inhibits human neovascularization in an ex vivo assay, which suggests that it may be useful as an antiangiogenic drug. The mechanism of these effects can be traced to the fact that orlistat prevents the display of the vascular endothelial growth factor (VEGF) receptor (VEGFR2/ KDR/Flk1) on the endothelial cell surface. Thus, orlistat is an antiangiogenic agent with a novel mechanism of action.—Browne, C. D., Hindmarsh, E. J., and Smith, J. W. Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor. FASEB J. 20, 2027–2035 (2006)
33
Dirk B. Mendel, Alexander Laird, Xiaohua Xin et al. · PubMed · 2003 · 2K citations
Medicine, Oncology, Pharmacology +15
Orlistat Is a Novel Inhibitor of Fatty Acid Synthase with Antitumor Activity
Steven J. Kridel, Fumiko Axelrod, Natasha Rozenkrantz et al. · Cancer Research · 2004 · 601 citations · Full text
Medicine, Oncology, Pharmacology +16